Quest PharmaTech (TSXV:QPT) Cash-to-Debt : 0.09 (As of Oct. 2023)

View and export this data going back to 1999. Start your Free Trial

What is Quest PharmaTech Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Quest PharmaTech's cash to debt ratio for the quarter that ended in Oct. 2023 was 0.09.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Quest PharmaTech couldn't pay off its debt using the cash in hand for the quarter that ended in Oct. 2023.

The historical rank and industry rank for Quest PharmaTech's Cash-to-Debt or its related term are showing as below:

TSXV:QPT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02 Med: 0.87 Max: No Debt
Current: 0.09

During the past 13 years, Quest PharmaTech's highest Cash to Debt Ratio was No Debt. The lowest was 0.02. And the median was 0.87.

TSXV:QPT's Cash-to-Debt is ranked worse than
94.85% of 1535 companies
in the Biotechnology industry
Industry Median: 6.49 vs TSXV:QPT: 0.09

Quest PharmaTech Cash-to-Debt Historical Data

The historical data trend for Quest PharmaTech's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Quest PharmaTech Cash-to-Debt Chart

Quest PharmaTech Annual Data

Trend

Jan14

Jan15

Jan16

Jan17

Jan18

Jan19

Jan20

Jan21

Jan22

Jan23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

0.90

0.66

0.51

0.38

Quest PharmaTech Quarterly Data
	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23
Cash-to-Debt	Get a 7-Day Free Trial															0.48	0.38	0.11	0.10	0.09

Competitive Comparison of Quest PharmaTech's Cash-to-Debt

For the Biotechnology subindustry, Quest PharmaTech's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Quest PharmaTech's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Quest PharmaTech's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Quest PharmaTech's Cash-to-Debt falls into.

Quest PharmaTech Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Quest PharmaTech's Cash to Debt Ratio for the fiscal year that ended in Jan. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.375	/	(1	+	0)
	=	0.38

Quest PharmaTech's Cash to Debt Ratio for the quarter that ended in Oct. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.094	/	(1	+	0)
	=	0.09

Quest PharmaTech (TSXV:QPT) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Quest PharmaTech Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Quest PharmaTech's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Quest PharmaTech (TSXV:QPT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Quest PharmaTech Inc (TSXV:QPT) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

8123 Roper Road NW, Edmonton, AB, CAN, T6E 6S4

Website

http://www.questpharmatech.com

Quest PharmaTech Inc is a Canadian-based pharmaceutical company developing targeted cancer therapy with its lead product MAb AR9.6, under development for a novel target- truncated O-glycans on MUC16 discovered at the University of Nebraska Medical Center. The company is also developing products utilizing proprietary transdermal delivery technologies with a focus on dermatology and wound healing applications.

Executives

Ragupathy Madiyalakan

Director

Quest PharmaTech (TSXV:QPT) Headlines

No Headlines